PECAM1 and neoplasm: Furthermore, CD31 immunostaining (Figure 9D) and MVD count (Figure 9F) confirmed that treatment with Sorafenib (50 mg/ kg) and 1 (40 mg/kg) significantly reduced tumor vascularization.